Inactive Instrument

Allied Corp. Stock price Other OTC

Equities

ALID

US0191141078

Pharmaceuticals

Sales 2022 0.17 Sales 2023 0.07 Capitalization 22.78M
Net income 2022 -15M Net income 2023 -10M EV / Sales 2022 289,040,315 x
Net Debt 2022 4.98M Net Debt 2023 5.65M EV / Sales 2023 394,366,816 x
P/E ratio 2022
-2.73 x
P/E ratio 2023
-2.13 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 48.93%
More Fundamentals * Assessed data
Dynamic Chart
Allied Corp. Reports Earnings Results for the First Quarter Ended November 30, 2023 CI
Allied Corp. Reports Earnings Results for the Full Year Ended August 31, 2023 CI
Allied Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2023 CI
Allied Corp. announced a financing transaction CI
Allied Corp. Signs Joint Venture with Blueberries Medical Corp. to Expand Product Offering and Bring Derivative Products to Global Markets CI
Allied Corp. Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2023 CI
Allied Corp. Reports Earnings Results for the First Quarter Ended November 30, 2022 CI
Allied Corp. Reports Earnings Results for the Full Year Ended August 31, 2022 CI
Allied Corp. Auditor Raises 'Going Concern' Doubt CI
Allied Corp. Successfully Executes on Another Sale & Export of Colombian Produced Cannabis Flower CI
Allied Corp. announced that it has received $1.47 million in funding CI
Allied Corp Receives The Brazilian Health Regulatory Agency Approval for Brazilian Import CI
Allied Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2022 CI
Allied Corp. Successfully Ships Second Commercial Cannabis Flower Export from Colombia to International Market CI
Allied Corp Successfully Ships First Commercial Cannabis Flower Export from Colombia to International Market CI
More news
Managers TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO 42 20-03-24
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member - 20-05-01
Chief Executive Officer - -
Corporate Officer/Principal 56 -
More insiders
Allied Corp. is an international medical cannabis production company. The Company is focused on the development of medicinal cannabis and psilocybin products for patients with conditions potentially suitable for treatment there with. Such conditions include anxiety, insomnia, anorexia, chronic pain, epilepsy, chemotherapy-induced nausea and vomiting, post-traumatic stress disorder (PTSD), Parkinson’s disease, Tourette syndrome, irritable bowel syndrome (IBS) and spasticity associated with multiple sclerosis (MS) and spinal cord injury (SCI)1. Its wholly owned subsidiaries include AM Biosciences, Allied US Products LLC, Tactical Relief LLC, Baleno Ltd., and Allied Colombia.
More about the company
  1. Stock
  2. Equities
  3. Stock Allied Corp.
  4. Stock Allied Corp. - Other OTC